Oculis Holding AG Logo

Oculis Holding AG

OCS | IC

Overview

Corporate Details

ISIN(s):
CH1242303498 (+1 more)
LEI:
5067005370C2KK324336
Country:
Switzerland
Address:
Bahnhofstrasse 7, 6300 Zug
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative treatments to save sight and improve eye care. The company's primary mission is to address significant unmet medical needs in ophthalmology through a patient-centric approach. Its pipeline features several investigational drug candidates, including OCS-01, a topical eye drop using its proprietary OPTIREACH® technology for Diabetic Macular Edema (DME); Licaminlimab (OCS-02) for Dry Eye Disease (DED); and Privosegtor (OCS-05), a neuroprotective agent for Acute Optic Neuritis. Oculis aims to develop highly differentiated, non-invasive, and potentially first-in-class therapies to transform the treatment paradigms for major eye diseases.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Oculis Holding AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-21 22:05
Earnings Release
Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri f…
Icelandic 20.6 KB
2025-08-21 22:05
Earnings Release
Oculis Reports Q2 2025 Financial Results and Provides Company Update
English 18.3 KB
2025-08-12 10:00
Report Publication Announcement
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtu…
English 4.2 KB
2025-08-01 10:00
Capital/Financing Update
Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF
Icelandic 8.1 KB
2025-08-01 10:00
Capital/Financing Update
Oculis Upsized Loan Facility to Access up to CHF 100 million
English 7.1 KB
2025-07-09 22:05
Board/Management Information
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 948 bytes
2025-06-09 22:05
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 940 bytes
2025-06-05 10:00
Post-Annual General Meeting Information
Oculis birtir niðurstöður aðalfundar 2025
Icelandic 7.7 KB
2025-06-05 10:00
Post-Annual General Meeting Information
Oculis Publishes Results of 2025 Annual General Meeting
English 6.4 KB
2025-06-03 23:00
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 949 bytes
2025-06-03 10:00
Regulatory News Service
Oculis to Participate in Upcoming June Investor Conferences
English 4.3 KB
2025-05-09 22:05
Pre-Annual General Meeting Information
Oculis birtir boð á aðalfund
Icelandic 4.6 KB
2025-05-09 22:05
Pre-Annual General Meeting Information
Oculis Publishes Invitation to the Annual General Meeting
English 4.2 KB
2025-05-09 21:05
Pre-Annual General Meeting Information
Oculis Publishes Invitation to the ..
Icelandic 4.6 KB
2025-05-09 21:05
Pre-Annual General Meeting Information
Oculis Publishes Invitation to the ..
English 4.2 KB

Automate Your Workflow. Get a real-time feed of all Oculis Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oculis Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Aran Research & Development (1982) Ltd. Logo
End-to-end product & machine development for plastics, medical, and industrial markets.
Israel ARAN
ARIX BIOSCIENCE PLC Logo United Kingdom ARIX
AroCell AB Logo Sweden AROC
Arterra Bioscience Logo
Develops sustainable active ingredients from plant cell cultures for diverse industries.
Italy ABS
Asarina Pharma AB Logo
Developed Sepranolone for neurological disorders like Tourette's, OCD, and menstrual migraine.
Sweden ASAP
Ascelia Pharma Logo
Developing novel drugs for rare cancer conditions, including an oral MRI contrast agent.
Sweden ACE
AVACTA GROUP PLC Logo
Developing targeted cancer therapies with a platform that delivers drugs directly to tumors.
United Kingdom AVCT
BenevolentAI Logo
AI-powered platform that analyzes biomedical data to accelerate drug discovery.
United Kingdom BAI
BerGenBio Logo
Develops first-in-class AXL inhibitors for cancer and severe respiratory infections.
Norway BGBIO
BioArctic Logo
Biopharma developing treatments & diagnostics for neurodegenerative diseases like Alzheimer's.
Sweden BIOA